{Reference Type}: Journal Article
{Title}: Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study.
{Author}: Ueno M;Shirakawa S;Tokumaru J;Ogi M;Nishida K;Hirai T;Shinozaki K;Hamada Y;Kitagawa H;Horiguchi A;
{Journal}: J Hepatobiliary Pancreat Sci
{Volume}: 31
{Issue}: 7
{Year}: 2024 Jul 27
{Factor}: 3.149
{DOI}: 10.1002/jhbp.1418
{Abstract}: <B>OBJECTIVE: </B>To describe the real-world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.<BR><B>METHODS: </B>Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look-back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection-induced treatment interruption were analyzed.<BR><B>RESULTS: </B>The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first-line regimens were S-1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011-September 2021). Patients who received monotherapies tended to be older. Biliary infection-induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0-145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0-92.0) days.<BR><B>CONCLUSIONS: </B>These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first-line treatment, and the management of biliary infections during systemic therapy.